The company specializes in developing therapeutic drugs that restore natural brain functioning by modulating the activity of cannabinoid molecules and inhibiting endocannabinoid transport across cell membranes. Synendos' innovative approach is based on first-in-class inhibitors that rebalance altered neurotransmission in different areas of the brain. The company's mission is to provide breakthrough safe and effective therapies for unmet needs in neuropsychiatric disorders, with a particular focus on post-traumatic stress disorder (PTSD). Synendos Therapeutics AG was founded in April 2019 as a spin-off of the University of Bern, and its inhibitors were designed and developed through a thorough med chem program in collaboration with a CRO.